Development and external validation of a machine learning model to predict central sensitization symptom burden in psoriatic arthritis
Objectives Central sensitization (CS) is a general mechanism of pain amplification. In psoriatic arthritis (PsA), it contributes to pain that is disproportionate to inflammation. We aimed to develop and externally validate machine learning (ML) models to identify clinically significant central sensitization symptom burden in PsA from routinely available clinical and patient-reported variables. Methods Models were developed in a cohort of 223 patients with PsA (CASPAR criteria) and externally validated in 50 patients from two referral centers. The outcome was a Central Sensitization Inventory (CSI) total score ≥40. Logistic Regression (LR) and Random Forest (RF) were developed using nested 5-fold stratified cross-validation with model-specific regularisation. The final models were then refitted on the entire development cohort, recalibrated using logistic recalibration, and independently evaluated in the external validation cohort. Results Elevated CS symptom burden (CSI ≥40) was present in 63.7% of patients internally and 70% externally. Both models discriminated well internally (AUROC 0.83 LR, 0.81 RF) and externally (AUROC 0.78, 95% CI 0.65–0.90, LR; 0.84, 95% CI 0.72–0.93, RF), with comparable performance between models, and were adequately calibrated after recalibration, with wider uncertainty in the external cohort. The main predictors, consistent across both models, were VAS pain, pain frequency, morning-stiffness duration, DAPSA and sex. Conclusions ML models built on routine variables can identify patients with PsA who have clinically significant CS symptom burden, with good internal and acceptable performance on preliminary external validation. LR and RF performed comparably, with LR offering a transparent, interpretable model and RF greater modelling flexibility. Such models may become an easily implemented assessment of elevated CS symptom burden in clinical practice for PsA patients’ management, pending further validation in larger, more diverse cohorts.
Authors
- Paolo Soda (ORCID: https://orcid.org/0000-0003-2621-072X)
- Francesca Tecce (ORCID: https://orcid.org/0000-0002-9513-5228)
- Riccardo Terribili (ORCID: https://orcid.org/0009-0001-8777-1187)
- Rosa Sicilia (ORCID: https://orcid.org/0000-0002-2513-0827)
- Paola Cipriani (ORCID: https://orcid.org/0000-0002-2000-4661)
- Guglielmo Giannini (ORCID: https://orcid.org/0009-0005-3367-2094)
- Piero Ruscitti (ORCID: https://orcid.org/0000-0003-3487-8551)
- Vanda Franco
- Luca Navarini (ORCID: https://orcid.org/0000-0001-8537-1510)
- Marta Vomero (ORCID: https://orcid.org/0000-0001-9744-5628)
- Annalisa Marino (ORCID: https://orcid.org/0000-0002-2511-7374)
- Damiano Currado (ORCID: https://orcid.org/0000-0003-1815-2304)
- Francesco De Vincenzo (ORCID: https://orcid.org/0000-0003-2795-6670)
- Francesca Saracino
- Roberto Giacomelli (ORCID: https://orcid.org/0000-0003-0670-9638)
- Stefano Gentileschi (ORCID: https://orcid.org/0000-0001-6658-1037)
- Erika Corberi
- Francesca Trunfio (ORCID: https://orcid.org/0009-0001-4199-6321)
- Valerio Guarrasi (ORCID: https://orcid.org/0000-0002-1860-7447)
- Onorina Berardicurti (ORCID: https://orcid.org/0000-0002-2808-1581)
- Leonardo Frascà (ORCID: https://orcid.org/0009-0001-8857-9410)
- Ludovica Lamberti
- Marco Salmè (ORCID: https://orcid.org/0009-0002-0269-8302)
Institutions
- University of Siena (IT)
- Università Campus Bio-Medico (IT)
- University of L'Aquila (IT)
- Saint Camillus International University of Health and Medical Sciences (IT)
- European University of Rome (IT)
- Campus Bio Medico University Hospital (IT)
- Link Campus University (IT)
- Umeå University (SE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3389/fimmu.2026.2013699
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00